ACC pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
20 of 25 arms with a reported figure. Choose arms to narrow the chart.
| Drug, trial | Population | Dose | Estimand | Comparator | ORR, % | mPFS, months | mOS, months | Hazard ratio | Other |
|---|---|---|---|---|---|---|---|---|---|
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) | R/M ACC, evaluable (n = 45) | Phase 1 doses (not stated in source) | Single arm | n/r | objective response rate: 35.6%, ASCO 2026 | n/r | n/r | n/r | disease control rate: 82.2%, ASCO 2026median duration of response: 7.4 months, ASCO 2026 |
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) | ACC with solid histology or high-grade transformation (n = 32, post hoc) | Phase 1 doses (not stated in source) | Single arm | n/r | objective response rate: 46.9%, ASCO 2026; post hoc | median progression-free survival: 7.8 months, ASCO 2026; post hoc | n/r | n/r | median duration of response: 6.4 months, ASCO 2026; post hoc |
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) | ACC safety population (n = 48) | Phase 1 doses (not stated in source) | Single arm | n/r | n/r | n/r | n/r | n/r | n/r |
| RGT-61159 at or below RP2D (mixed doses)RGT-61159 Phase 1a/b | R/R ACC, evaluable (n = 39) | at or below RP2D (mixed doses) | Single arm | n/r | partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending | n/r | n/r | n/r | disease control rate: 84.6%, ASCO 2026, preliminary |
| REM-422 24 mgARIA | R/M ACC, MYB biomarker positive at RP2D (n = 7) | 24 mg | Single arm | n/r | objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7) | n/r | n/r | n/r | disease control rate: 100%, ASCO 2026 |
| REM-422 12 to 48 mgARIA | biomarker-positive R/M ACC (n = 30) | 12 to 48 mg | Single arm | n/r | n/r | n/r | n/r | n/r | any target-lesion reduction: 70%, cutoff 01.07.2026target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026 |
| REM-422 24 mgARIA | all patients at RP2D (n = 15) | 24 mg | Single arm | n/r | n/r | n/r | n/r | n/r | n/r |
| Osugacestat (AL101, BMS-906024) 4 mgACCURACY | R/M ACC with NOTCH1 to 4 activating mutation (n = 45) | 4 mg | Single arm | n/r | responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024 | n/r | median overall survival: 9.3 months, final | n/r | n/r |
| Osugacestat (AL101, BMS-906024) 6 mgACCURACY | R/M ACC with NOTCH activating mutation (n = 42) | 6 mg | Single arm | n/r | responders (CR or PR): 2 patients (of 42), final | n/r | median overall survival: 9.4 months, final | n/r | n/r |
| Lenvatinib (off Label) 24 mgLenvatinib MSK Phase 2 | progressive R/M ACC (n = 32 evaluable) | 24 mg | Single arm | n/r | objective response rate: 15.6%, primary analysis | median progression-free survival: 17.5 months, 8 progression events | n/r | n/r | n/r |
| Lenvatinib (off Label) 24 mgACC-LEN14 | R/M salivary ACC (n = 26 evaluable) | 24 mg | Single arm | n/r | objective response rate: 11.5%, primary analysis | median progression-free survival: 9.1 months, primary analysis | median overall survival: 27 months, primary analysis | n/r | n/r |
| Lenvatinib (off Label) not stated in sourceLenvatinib + pembrolizumab | progressive R/M ACC (n = 17 evaluable) | not stated in source | Single arm | n/r | objective response rate: 6%, ASCO 2023 (search record) | n/r | n/r | n/r | n/r |
| Axitinib (off Label) 5 mgAxitinib vs observation (randomized Phase 2) | R/M ACC with progression within 9 months (n = 60 total) | 5 mg | ITT | observation | objective response rate: 0%, primary analysis | median progression-free survival: 10.8 months, primary analysis6-month progression-free survival: 73%, 6 months | n/r | progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline | disease control rate: 100%, primary analysis |
| Axitinib (off Label) noneAxitinib vs observation (randomized Phase 2) | R/M ACC with progression within 9 months | none | ITT | n/r | n/r | median progression-free survival: 2.8 months, primary analysis6-month progression-free survival: 23%, 6 months | median overall survival: 27.2 months, axitinib median not reached; P 0.226 | n/r | disease control rate: 51.9%, primary analysis |
| Axitinib (off Label) axitinib 5 mg twice daily + avelumabAxitinib + avelumab Phase 2 (MD Anderson) | R/M ACC (n = 28 evaluable) | axitinib 5 mg twice daily + avelumab | Single arm | n/r | confirmed objective response rate: 18%, primary analysis | median progression-free survival: 7.3 months, primary analysis | median overall survival: 16.6 months, primary analysis | n/r | n/r |
| Axitinib (off Label) as aboveAxitinib + avelumab Phase 2 (MD Anderson) | ACC-I (exploratory biomarker analysis of 28 patients) | as above | Single arm | n/r | n/r | median progression-free survival: 1.8 months, updated analysis; exploratory | n/r | n/r | n/r |
| Axitinib (off Label) as aboveAxitinib + avelumab Phase 2 (MD Anderson) | ACC-II (exploratory) | as above | Single arm | n/r | n/r | median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I | n/r | n/r | n/r |
| Rivoceranib 700 mgRivoceranib Phase 2 | R/M ACC (n = 80; 72 evaluable) | 700 mg | Single arm | n/r | objective response rate (investigator): 15.3%, primary analysisobjective response rate (independent review): 9.7%, primary analysis | median progression-free survival: 9 months, primary analysis | n/r | n/r | median duration of response (investigator): 14.9 months, primary analysis |
| Amivantamab not stated in sourceAmivantamab in ACC | ACC (n = 21) | not stated in source | Single arm | n/r | responders: 1 patients (of 21), results posted 05.08.2026 | median progression-free survival: 4.6 months, results posted 05.08.2026 | n/r | n/r | n/r |
| Regorafenib (off Label) not stated in sourceRegorafenib in ACC | progressive R/M ACC (n = 38) | not stated in source | Single arm | n/r | responders (CR or PR): 1 patients (of 38), results posted 09.10.2025 | n/r | n/r | n/r | n/r |
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.